Home/Pipeline/Early Detection of Parkinson's (MJFF Consortium)

Early Detection of Parkinson's (MJFF Consortium)

Parkinson's Disease

ResearchActive

Key Facts

Indication

Parkinson's Disease

Phase

Research

Status

Active

Company

Oxford Brain Diagnostics

About Oxford Brain Diagnostics

Oxford Brain Diagnostics is a private, commercial-stage diagnostics company leveraging its FDA-cleared and breakthrough-designated MRI biomarker platform to quantify cortical microstructure changes associated with neurodegeneration. Its core technology, CDM®, provides novel endpoints for clinical trials and tools for clinicians, positioning it as a partner for biopharma and a contributor to precision neurology. The company is actively engaged in partnerships and research grants, indicating a transition from technology validation to commercial application in a high-need market.

View full company profile

Therapeutic Areas

Alzheimer's Disease Parkinson's Disease Neurodegenerative Diseases

Other Parkinson's Disease Drugs

Drug	Company	Phase	Status
NPT200-11	Neuropore Therapies	Phase 1	Partnered (UCB Pharma), status unclear
NUZ-001	Neurizon Therapeutics	Preclinical	Active
VXX-301	Vaxxinity	Preclinical	Pipeline
BAN2802	BioArctic	Phase 1	Active
CNM-Au8	Clene	Phase 2	Active
hpSC-Derived Neural/Dopaminergic Cells	International Stem Cell	Preclinical/Early Clinical	Inferred Active
SLS-004	Seelos Therapeutics	Preclinical	Research
SLS-007	Seelos Therapeutics	Preclinical	Research
Parkinson's Disease Portfolio (Platform-derived)	WD Pharmaceutical	Not Disclosed (Likely Preclinical/Early Clinical)	Active
UX-DA001	UniXell	Phase 1	Active, with trials ongoing in China and FDA IND cleared in U.S. (as of April 2025)
Parkinson's Disease Research	ProgenaBiome	Research	Active
A9 Dopaminergic Neuron Therapy	Trailhead Biosystems	Pre-clinical	Active